Ionis to hold donidalorsen Phase 3 data webcast

Rhea-AI Summary

Ionis Pharmaceuticals (NASDAQ: IONS) announced a live webcast scheduled for May 31, 2024, at 8:00 a.m. Eastern Time to discuss the donidalorsen Phase 3 OASIS-HAE study results. These results will be presented during three late-breaking oral presentations at the 2024 EAACI Annual Meeting in Valencia, Spain. The webcast and a -time replay can be accessed at the Ionis website.

Positive

• Ionis will present donidalorsen Phase 3 OASIS-HAE study results.
• Results to be shared in three late-breaking oral presentations at the EAACI Annual Meeting.
• Scheduled webcast allows for real-time investor and stakeholder engagement.

Negative

• Webcast interest is highly dependent on positive study outcomes.
• time availability for the webcast replay may restrict access.

Webcast scheduled for Friday, May 31 at 8:00 a.m. Eastern Time

CARLSBAD, Calif., May 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Friday, May 31^th at 8:00 a.m. Eastern Time to discuss the donidalorsen Phase 3 OASIS-HAE and OASISplus (Open-Label Extension and Switch cohorts) study results that will be presented in three late-breaking oral presentations at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Valencia, Spain.

The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionispharma.com and follow us on X (Twitter) and LinkedIn.

Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – info@ionisph.com – 760-603-2331

Ionis Pharmaceuticals Media Contact:
Hayley Soffer – CorporateCommunications@ionisph.com – 760-603-4679

View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-hold-donidalorsen-phase-3-data-webcast-302156276.html

SOURCE Ionis Pharmaceuticals, Inc.

FAQ

When is the Ionis donidalorsen Phase 3 data webcast?

The Ionis donidalorsen Phase 3 data webcast is scheduled for May 31, 2024, at 8:00 a.m. Eastern Time.

What will be discussed in the Ionis webcast on May 31, 2024?

The webcast will discuss the results of the donidalorsen Phase 3 OASIS-HAE and OASISplus study.

Where can I access the Ionis donidalorsen Phase 3 data webcast?

The webcast can be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events with a replay available for a time.

What event will feature the donidalorsen Phase 3 study results?

The results will be featured in three late-breaking oral presentations at the 2024 EAACI Annual Meeting in Valencia, Spain.

What is the focus of Ionis Pharmaceuticals' upcoming webcast?

The focus will be on the donidalorsen Phase 3 OASIS-HAE and OASISplus study results.